Resumen de First Monoclonal Antibody Against Anthrax
* Raxibacumab is the first monoclonal antibody approved for the treatment and (in some cases) prevention of inhalational anthrax.
* Data on the efficacy of raxibacumab are limited and were obtained from animal studies. Human safety trials found that infusion reactions are possible. Other adverse effects weren't serious.
